Diabetes

Pioglitazone associated with lower blood leptin in diabetes

(HealthDay)—Compared to placebo, pioglitazone is associated with significantly lower blood leptin levels in patients with type 2 diabetes, according to a meta-analysis published online Dec. 1 in the Journal of Diabetes ...

Diabetes

Pioglitazone improves left ventricular diastolic function

(HealthDay)—Pioglitazone improves whole-body and myocardial insulin sensitivity, left ventricular (LV) diastolic function, and systolic function in patients with type 2 diabetes, according to a small study published online ...

Neuroscience

Greater benefit for pioglitazone in high-risk patients post stroke

(HealthDay)—For patients after an ischemic stroke or transient ischemic attack, pioglitazone is associated with greater benefit for those at higher risk for stroke or myocardial infarction (MI), according to a study published ...

Diabetes

Ipragliflozin beneficial in T2DM complicated by liver disease

(HealthDay)—For patients with type 2 diabetes and nonalcoholic fatty liver disease (NAFLD), ipragliflozin exerts beneficial effects on NAFLD and glycemic control, similar to pioglitazone, according to a study published ...

Diabetes

Exenatide, pioglitazone effective for poorly controlled T2DM

(HealthDay)—For patients with long-standing poorly controlled type 2 diabetes mellitus (T2DM) on metformin plus a sulfonylurea, combination therapy with exenatide and pioglitazone is effective and safe, according to a study ...

Diabetes

Pioglitazone cuts diabetes risk after ischemic stroke, TIA

(HealthDay)—For insulin-resistant patients with recent ischemic stroke or transient ischemic attack, pioglitazone is associated with reduced risk of diabetes, according to a study published online July 27 in Diabetes Care.

Cardiology

Diabetes drug may prevent recurring strokes

Pioglitazone, a drug used for type 2 diabetes, may prevent recurrent stroke and heart attacks in people with insulin resistance but without diabetes. The results of the Insulin Resistance Intervention after Stroke (IRIS) ...

Alzheimer's disease & dementia

Diabetes medication reduces dementia risk

Treating people with type 2 diabetes, also known as 'age-related diabetes' with antidiabetics reduces their risk for Alzheimer's and other types of dementia. The risk is most significantly reduced by the drug pioglitazone. ...

page 1 from 2

Pioglitazone

Pioglitazone is a prescription drug of the class thiazolidinedione (TZD) with hypoglycemic (antihyperglycemic, antidiabetic) action. Pioglitazone is marketed as trademarks Actos in the USA, Canada, the UK and Germany, Glustin in Europe,"Glizone" and "Pioz" in India by Zydus CND and USV respectively and Zactos in Mexico by Takeda Pharmaceuticals. Actos was the tenth-best selling drug in the U.S. in 2008, with sales exceeding $2.4 billion. Its cardiovascular safety profile compares favorably with rosiglitazone (Avandia), which was withdrawn after concerns about an increased risk of cardiac events, but pioglitazone has subsequently been found to be associated with bladder tumors and has been withdrawn in some countries.

This text uses material from Wikipedia, licensed under CC BY-SA